Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan in PAH-induced Right Heart Failure
NCT05569655Unknown
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of tolvaptan in right-sided heart failure (2 arms), sponsored by Chinese Pulmonary Vascular Disease Research Group. Primary endpoints: Changes in body weight at 7 days and Changes in urine volume at 7 days. Status: unknown.
02
Drugs
tolvaptan
03
Conditions
right-sided heart failure
Beyond the preview
Go deeper on NCT05569655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569655.